GeoVax Labs (NASDAQ:GOVX) Releases Quarterly Earnings Results, Beats Estimates By $0.88 EPS

GeoVax Labs (NASDAQ:GOVX) issued its quarterly earnings results on Thursday. The company reported ($2.62) earnings per share for the quarter, beating the consensus estimate of ($3.50) by $0.88, FiscalAI reports.

GeoVax Labs Stock Down 3.1%

Shares of GeoVax Labs stock traded down $0.04 during trading hours on Thursday, reaching $1.26. 125,676 shares of the stock traded hands, compared to its average volume of 213,543. The company has a 50 day moving average price of $1.42 and a 200 day moving average price of $4.84. The firm has a market capitalization of $3.65 million, a price-to-earnings ratio of -0.04 and a beta of 3.36. GeoVax Labs has a one year low of $0.96 and a one year high of $34.75.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GOVX shares. Wall Street Zen downgraded GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a report on Tuesday, April 21st. Finally, D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, GeoVax Labs has a consensus rating of “Reduce” and an average target price of $150.00.

Institutional Investors Weigh In On GeoVax Labs

Large investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of GeoVax Labs during the 4th quarter valued at about $99,000. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs during the 4th quarter valued at about $104,000. Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter valued at about $253,000. Finally, HRT Financial LP bought a new stake in shares of GeoVax Labs during the 4th quarter valued at about $31,000. 6.09% of the stock is currently owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.